GlassScriptPhysician profile
Mohammed A Hussain
NPI 1649339441
$4,608.09
in general payments reported to CMS, 2019-2025
32 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $612 · 2021: $606 · 2022: $332 · 2023: $492 · 2024: $1,918 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,482 · Travel and Lodging: $1,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.58 |
| Travel and Lodging | $1,075.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,734.04 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $259.33 | 2021-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $244.58 | 2019-2024 | Rybelsus, Ozempic |
| Kowa Pharmaceuticals America, INC. | $228.65 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $222.38 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.99 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $181.37 | 2019-2021 | |
| Pfizer INC. | $166.08 | 2019-2025 | |
| Preventric Diagnostics, INC. | $154.21 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $124.23 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $113.29 | 2021 | |
| Glaxosmithkline, LLC. | $108.18 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.65 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $72.38 | 2019-2025 | Verzenio, Jaypirca |
| Exact Sciences Corporation | $68.44 | 2023-2025 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $66.00 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $64.76 | 2023 | Arcalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $62.58 | 2023-2024 | Ninlaro, Iclusig |
| Ardelyx, INC. | $58.82 | 2024 | Ibsrela |
| Amarin Pharma, INC. | $58.08 | 2020-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $50.47 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $47.60 | 2023 | Inpefa |
| Ascensia Diabetes Care US INC. | $44.73 | 2024 | |
| Ucb, INC. | $43.25 | 2020 | |
| Daiichi Sankyo INC. | $23.83 | 2023 | Enhertu |
| Pharmaessentia USA Corporation | $20.33 | 2024 | Besremi |
| Allergan, INC. | $20.32 | 2019 | |
| Merck Sharp & Dohme LLC | $17.74 | 2021 | |
| Esperion Therapeutics, INC. | $17.00 | 2021 | |
| Lucid Diagnostics INC. | $15.31 | 2024 | |
| Itamar Medical INC | $14.47 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.